.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Healthtrust
Accenture
Citi
Queensland Health
Farmers Insurance
Julphar
Merck
Dow

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,169,213

« Back to Dashboard

Which drugs does patent 9,169,213 protect, and when does it expire?


Patent 9,169,213 protects BELVIQ XR and BELVIQ and is included in two NDAs. There have been zero Paragraph IV challenges on Belviq XR and Belviq

This patent has eleven patent family members in ten countries.

Summary for Patent: 9,169,213

Title:Method of weight management
Abstract: Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
Inventor(s): Sanchez; Matilde (Alexandria, VA), Shanahan; William R. (Del Mar, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:14/242,442
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► Subscribe
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,169,213

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2886875► Subscribe
Japan2015534563► Subscribe
Japan2017101078► Subscribe
South Korea20150070249► Subscribe
Mexico2015004532► Subscribe
New Zealand631318► Subscribe
Australia2012392187► Subscribe
Argentina088670► Subscribe
Philippines12015500733► Subscribe
Uruguay34436► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Accenture
Moodys
Deloitte
Medtronic
McKesson
UBS
Julphar
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot